Sanofi Reports Phase 3 Results for Amlitelimab in Prurigo Nodularis

Sanofi today announced Phase 3 trial results for amlitelimab in adults with moderate-to-severe prurigo nodularis (PN). The trial met its primary endpoint, demonstrating a statistically significant improvement in IGA 0/1 response rate at week 24 compared to placebo. Amlitelimab is a fully human anti-OX40L monoclonal antibody that blocks OX40L signaling, a key driver of T-cell-mediated inflammation in PN. These results support amlitelimab as a potential new treatment option for prurigo nodularis, expanding its potential indications beyond atopic dermatitis.